- Home
- TRC vs RCKT Comparison
TRC vs RCKT Comparison
Compare TRC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRC | RCKT |
|---|---|---|
| Founded | 1843 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.2M | 401.6M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRC | RCKT |
|---|---|---|
| Price | $17.62 | $3.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.73 |
| AVG Volume (30 Days) | 96.7K | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $37,830,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $64.28 |
| P/E Ratio | $1,773.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.31 | $2.53 |
| 52 Week High | $21.31 | $5.45 |
Technical Indicators
Market Signals| Indicator | TRC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 33.60 | 40.19 |
| Support Level | $15.43 | $2.95 |
| Resistance Level | $19.78 | $3.63 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 0.00 | 7.05 |
Price Performance
Historical ComparisonAbout TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company. It has six reporting segments: Real Estate - Commercial/Industrial, Multifamily, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.